Cross-Sector entity
Across a 25-day span, the pace is roughly 2 stories per week. The busiest single day carried 3. Psilocybin is most often covered alongside FDA, which appears in 3 of these 7 stories. Coverage clusters in clinical-trial, which accounts for 3 of those 7, with the remainder spread across 2 other categories.
7 verified stories tracked
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 57 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Across a 25-day span, the pace is roughly 2 stories per week. The busiest single day carried 3. Psilocybin is most often covered alongside FDA, which appears in 3 of these 7 stories. Coverage clusters in clinical-trial, which accounts for 3 of those 7, with the remainder spread across 2 other categories. Negative sentiment appears in 0% of the tracked stories. Each carries 2.1 original sources on average. We currently track 7 Cross-Sector stories that mention Psilocybin, published between February 21, 2026 and March 17, 2026.
Computed from the 7 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Psilocybin. Shared-story counts are live from our verified record — not editorial picks.
Valuation Period
Expected timeframe for determining the fair market value of the equity investment.
Palliative Care Findings
New research confirms high efficacy rates for mitigating end-of-life distress in oncology settings.
Option Exercised
PsyLabs officially triggers the put option, requiring an equity investment from PBM.
Strategic Investment Announced
Psyence BioMed announces it will make an equity investment in PsyLabs at fair market value.
Put Option Established
Psyence BioMed and PsyLabs enter into a strategic put option agreement.
Phase 3 Trials
Large-scale multi-site trials aim to provide definitive data for regulatory approval.
SAP Expansion
Canada formally expands the Special Access Program to include restricted psychedelic substances.
Canadian Exemptions
Health Canada grants the first legal exemptions for psilocybin use to four terminally ill patients.
Regulatory Shift
Health Canada begins granting Section 56 exemptions for terminally ill patients.
FDA Breakthrough Status
FDA grants Breakthrough Therapy designation to psilocybin for treatment-resistant depression.
Foundational Research
Johns Hopkins and NYU publish landmark studies on psilocybin for cancer-related distress.
A new comparative study reveals that psychedelic-assisted therapy significantly exceeds the efficacy of standard nicotine patches for long-term smoking cessation. The findings suggest a paradigm shift in treating nicotine addiction, moving from continuous replacement to episodic, transformative intervention.
A landmark study has demonstrated that a single dose of psilocybin, paired with psychological support, significantly outperforms traditional nicotine replacement therapies for long-term smoking cessation. The findings suggest a paradigm shift in treating substance use disorders through psychedelic-assisted therapy.
Emerging clinical research indicates that psilocybin-assisted therapy can significantly alleviate existential dread and depression in terminally ill patients. This development marks a potential paradigm shift in palliative care, moving beyond physical pain management to address deep-seated psychological trauma.
Clinical research into psilocybin-assisted therapy is demonstrating significant potential in mitigating existential distress and depression among terminally ill patients. These findings are driving a re-evaluation of palliative care protocols and accelerating the push for expanded regulatory access to psychedelic-based treatments.
Source: ottawasun.com · edmontonsun.com
Psyence Biomedical Ltd. (Nasdaq: PBM) has announced a strategic equity investment in PsyLabs Ltd. after the manufacturer exercised its rights under a previously established put option agreement. This move strengthens the relationship between the biopharmaceutical developer and its primary supplier of nature-derived psychedelic compounds.
Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a pre-existing put option agreement. The transaction reinforces the vertical integration between the clinical-stage developer and its primary source of pharmaceutical-grade, nature-derived psychedelic compounds.
Psyence Biomedical Ltd. (Nasdaq: PBM) has confirmed a strategic equity investment in PsyLabs following the exercise of a previously established put option. This move deepens the integration between the biopharmaceutical developer and its primary manufacturer of pharmaceutical-grade psychedelic compounds.
Source: CBJ (ca) · manilatimes.net
